The emergence of the drug represents a significant breakthrough in the management of type 2 diabetes. This novel therapy, functioning as a dual GIP and GLP-1 target stimulator, has exhibited impressive improvements in glucose control and body weight reduction in clinical research. Researchers are encouraged that the medication could offer a improve